Ayurveda
KutkiPicrorhiza kurroa
A very bitter Himalayan root used in Ayurveda for the liver and as a purgative. One 33-person trial in viral hepatitis; reviews report loose stools at higher doses.
- Botanical name
- Picrorhiza kurroa
- Part used
- root and rhizome
- Also called
- Sanskrit Katuki, Katurohini; Hindi Kutki, Katuka; Kutaki, Picrorhiza
- Used in
- Ayurveda
- Taken for
- Liver and bile, Constipation, Indigestion
- Sold as
- capsules, powder, extract, tablets
What kutki is
Kutki is the dried root and rhizome of Picrorhiza kurroa, a small perennial herb that grows at high altitude in the Himalayas. The name Katuki means “the bitter one,” and a related Sanskrit name, Katumbhara, is glossed in a 2023 review as “full of bitter principles.” A 2021 review lists the plant as endangered because of wild harvest.
It is sold as a root powder, in capsules, and as extracts standardized to picrosides I and II, the iridoid compounds that researchers treat as its main actives. In one trial the capsules contained 2.72 to 2.88 mg of picroside I and 5.50 to 6.00 mg of picroside II each. In Ayurvedic practice it is also an ingredient in compound formulas for the liver and digestion, and several of the small clinical studies described below tested such formulas rather than the root alone.
What the traditions use it for
Ayurveda (about Ayurveda)
An Ayurvedic college monograph gives kutki a bitter taste (rasa), light and dry qualities (guna), a cooling potency (virya) and a pungent after-digestion effect (vipaka). The tradition says it calms kapha and pitta, two of its three governing principles (doshas). Its listed actions include bhedani, meaning it breaks up and moves the bowels, deepana, meaning it kindles digestion, and hridya, which relates to the heart. The monograph’s indications are prameha (a group of urinary and metabolic disorders), breathlessness, cough, skin disease and intestinal worms.
A 2023 review of the plant in Ayurveda describes further traditional actions: lekhaneeya (scraping away accumulations), rechani (laxative), bhedaneeya (purgative), and relief of jaundice and of liver enlargement. It says the root is used predominantly in traditional practice for liver, bile and gut disorders, and it notes use for intermittent fevers.
The constituents
The picrosides, iridoid glycosides, are the compounds most tied to the root’s liver research, and a 2023 review says they emerged as the active molecules in experimental and clinical studies. A 2022 review also lists alkaloids, cucurbitacins, phenolics and terpenes in the plant. In the laboratory, a root preparation given orally at 200 mg/kg to rats with galactosamine-induced liver injury significantly lowered liver fat and the liver enzymes GOT and GPT (p less than 0.05). That is a toxin-injury rat model, not a human finding, and the picrosides’ effect on the human gut has not been studied.
The human evidence
The best-known human result is a 1996 randomized, double-blind, placebo-controlled trial in people with acute viral hepatitis (HBsAg negative): 15 received 375 mg of root powder three times a day for 2 weeks and 18 received placebo. Differences in bilirubin, SGOT and SGPT were significant. The time for serum bilirubin to fall to an average of 2.5 mg% was 27.44 days with kutki and 75.9 days with placebo. It was a small trial, and its subject is liver inflammation, not digestion.
A 2023 review gathered the other clinical work in a table. Most studies are small, several tested compound formulas that include other herbs, and the authors themselves call the clinical evidence sporadic with variable outcomes. Examples include an open-label study of kutaki processed in guduchi and given with atorvastatin in 32 people (2 g of kutki twice daily for 3 months, no adverse events reported) and a single-arm study of a kutki-containing powder in 11 people with fatty liver inflammation (6 g twice daily for 180 days), in which two people had loose stools 2 to 3 times a day during the first 8 days.
On the hepatotoxicity question: the root is promoted for the liver, and in the reviews and abstracts we read we found no case report attributing liver injury to kutki. The 2023 review does say it has been reported to cause toxicity if not used in an appropriate dose for the correct indication. We found no trial of kutki for constipation or other bowel complaints.
| Study | Dose | What it found |
|---|---|---|
| Randomized, double-blind, placebo-controlled trial, 33 people with acute viral hepatitis (15 kutki, 18 placebo) PMID 9715310 | 375 mg root powder three times daily for 2 weeks | Significant differences in bilirubin, SGOT and SGPT; days for bilirubin to fall to 2.5 mg%: 27.44 (kutki) versus 75.9 (placebo) |
| Open-label study, 32 people, kutaki processed in guduchi given with atorvastatin (reported in a 2023 review) PMID 35659739 | 2 g kutki twice daily plus atorvastatin 20 mg twice daily, 3 months | No adverse events reported |
| Single-arm study, 11 people with fatty liver inflammation, kutki-containing powder (reported in a 2023 review) PMID 35659739 | 6 g twice daily for 180 days | Two people had loose stools 2 to 3 times a day for the first 8 days |
Doses, in trials and in practice
The viral hepatitis trial used 375 mg of root powder three times a day for 2 weeks. A 2023 review gives typical adult use of 300 to 500 mg of rhizome powder two to three times a day, and 2 to 4 g as a single dose when a laxative effect is intended. The Ayurvedic college monograph lists 0.5 to 1 g of root. Compound-formula studies used 2 g twice daily (with guduchi processing) and 6 g twice daily.
The amounts above are what trials and pharmacopoeias record, not a dose for you; your medicines and conditions change the answer, and a clinician or pharmacist who knows them is the person to ask.
What is known about safety
The 2023 review’s authors, drawing on their clinical experience, report increased bowel frequency, diarrhea, abdominal gurgling and colic with kutki, and state that it has been reported to cause toxicity if not used in an appropriate dose for the correct indication. Its tabulated studies list no adverse events apart from loose stools in 2 of 11 people in the single-arm study. The sources we read give no pregnancy or breastfeeding data, and the review names no group to avoid it.
Quality is a separate matter. JAMA studies of Ayurvedic medicines sold in the United States found lead, mercury or arsenic in 14 of 70 products from Boston-area stores (2004) and in 20.7% of 193 products ordered online (2008), with the 2008 study finding metals in 40.6% of the mineral-and-metal preparations (rasa shastra) against 17.1% of the others. These findings concern those Ayurvedic medicines, not kutki root as a whole.
Where it meets prescription medicines
We did not find a published interaction study of kutki. One open-label study in the 2023 review gave kutki with atorvastatin 20 mg twice daily and reported no adverse events, but that is a safety observation in 32 people, not an interaction test. We found no study that measured whether kutki changes the blood levels of any medicine, so the question is open.
From the herb to a product that fits you
The quiz takes about three minutes, asks what you have tried and which medicines you take, and shows the products whose trials and labels fit, with the reasons.
Take the quizHerbs that sit beside it
What people want to know
Is kutki safe for the liver?
We found no case report of liver injury attributed to kutki in the reviews and abstracts we read, and the small human studies listed no liver-related adverse events. The 2023 review does state that it has been reported to cause toxicity if not used in an appropriate dose for the correct indication, and the evidence base is small.
What did the viral hepatitis trial find?
In 33 people with acute viral hepatitis, 375 mg of root powder three times a day for 2 weeks was compared with placebo. Bilirubin took 27.44 days to fall to 2.5 mg% with kutki and 75.9 days with placebo. The trial was small and is about hepatitis, not digestion.
Does kutki cause loose stools?
The authors of a 2023 review report increased bowel frequency, diarrhea, abdominal gurgling and colic, and Ayurvedic texts class the root as a laxative and purgative at larger doses. In one single-arm study, 2 of 11 people had loose stools for the first 8 days.
Why is kutki so bitter?
The name Katuki and the related Katumbhara point to this: a 2023 review glosses Katumbhara as full of bitter principles. Bitterness is one of the tradition’s taste categories, and kutki is classed as bitter.
Is it the same as picroliv or kutkin?
They are related. Kutkin and picroliv are picroside-rich preparations made from the root, and the picrosides I and II are the compounds measured in standardized capsules. A label may list the root powder or a standardized fraction, and their doses are not interchangeable.
Sources
- Vaidya AB et al., "Picrorhiza kurroa (Kutaki) Royle ex Benth as a hepatoprotective agent--experimental & clinical studies", J Postgrad Med 1996;42(4):105-108 pubmed.ncbi.nlm.nih.gov/9715310
- Raut A et al., "Picrorhiza kurroa, Royle ex Benth: Traditional uses, phytopharmacology, and translational potential in therapy of fatty liver disease", J Ayurveda Integr Med 2023;14(1):100558 pubmed.ncbi.nlm.nih.gov/35659739
- Almeleebia TM et al., "Pharmacological and Clinical Efficacy of Picrorhiza kurroa and Its Secondary Metabolites: A Comprehensive Review", Molecules 2022;27(23):8316 pubmed.ncbi.nlm.nih.gov/36500409
- Mehta S, Sharma AK et al., "Advances in Ethnobotany, Synthetic Phytochemistry and Pharmacology of Endangered Herb Picrorhiza kurroa (Kutki): A Comprehensive Review (2010-2020)", Mini Rev Med Chem 2021 pubmed.ncbi.nlm.nih.gov/33797375
- Shri Dhanwantry Ayurvedic College & Hospital, Chandigarh, Dravyaguna monograph: Katuki www.sdach.ac.in/about-dravyaguna-vigyan/dravyaguna-vigyan-blogs/katuki
- Saper RB et al., "Heavy metal content of ayurvedic herbal medicine products", JAMA 2004;292(23):2868-2873 pubmed.ncbi.nlm.nih.gov/15598918
- Saper RB et al., "Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet", JAMA 2008;300(8):915-923 pubmed.ncbi.nlm.nih.gov/18728265